Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events

Abstract

Immune-related cutaneous adverse events (ircAEs) commonly occur in patients on treatment with immune checkpoint inhibitors and can significantly reduce patient quality of life. These are often treated with immunomodulatory agents, including glucocorticoids, immunosuppressants, and biologics. While often effective at managing symptoms, these therapies can cause several adverse events which may limit their use. In addition, immunomodulatory agents should be used with particular caution in patients receiving immunotherapy, as the efficacy of the oncologic regimen may potentially be undermined. In this review, we summarize the safety of systemic therapies that are used in the management of ircAEs, with a particular focus on the resultant risk of secondary tumor progression in patients with active cancer.

A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers

“…Moderate to severe side effects require additional interventions and occasionally even complete discontinuation of therapy. System inflammation syndromes like severe colitis, hepatitis, or osteoporosis are often mediated by immunomodulators such as corticosteroids, immunosuppressive antibodies (e.g., tocilizumab), and other inhibitors (e.g., cyclosporine, azathioprine, methotrexate) [ 40 , 41 ]. Tocilizumab, a monoclonal antibody that targets the interleukin-6 receptor, was also shown to be effective in the case of severe cytokine release syndrome that can occur due to a combination of immune therapies [ 39 ].…”